Introduction

Atherosclerosis & cholesterol
The link between cardiovascular disease (CVD) and lipids has been appreciated for a long time, but the individual role of specific lipids in predisposition to disease is constantly under question. Cardiovascular disease, including myocardial infarction (MI), heart failure, and stroke, represents the leading cause of mortality worldwide, accounting for half of the total number of deaths in the developed world (World Health Organization, 2002). CVD will result in 20. Atherosclerosis, or "athero" as we call it, is a condition underlying most cardiovascular diseases (Berliner et al. 1995) and results from an imbalance between uptake and efflux of 84 cholesterol by macrophages in the wall of blood vessels. It is the progressive buildup of plaque in the arteries over time causing narrowing of the vessels and severely limiting blood flow in advanced cases. Rupture of the plaque and thrombosis may result in complete occlusion of the vessel and, ultimately, myocardial infarction or stroke (Berliner and Glass) . For many of us, this plaque starts building up in our arteries in early adulthood and gets worse over time (Fig.2 , for illustrative purposes). Fig. 2 . Atherosclerosis; the progressive build up of plaque in arteries over time.
Cholesterol
Is a fatty substance, also called a lipid, which is produced by the liver. It is also found in foods high in saturated fat, like fatty meats, egg yolks, shellfish, and whole-milk dairy products. Since lipids are insoluble in blood, they are carried in association with proteins as lipoproteins, which allows their transport around the body. Lipoprotein complexes present in the serum have been the focus of much study in the etiology of cardiovascular disease (Goldstein, 1990 ).
There are five types of lipoproteins, and this classification is based on their densities. Those of lowest density, the chylomicrons, contain more lipids and less protein than those at the other extreme, high-density lipoproteins (HDLs). Between these classes are the very low-density lipoproteins (VLDLs), low-density lipoproteins (LDLs), and intermediate-density lipoproteins (IDLs). Plasma cholesterol is carried from the intestine and the liver to peripheral tissues largely in the form of LDLs. Most clinical studies concentrate on the relative abundance of HDLs and LDLs in the serum. LDL cholesterol is considered "bad" because too much of it in the blood stream can contribute to the progression of atherosclerosis, the buildup of plaque in the arteries. HDL cholesterol, on the other hand, is considered "good", it appears to be protective against cardiovascular disease (Miller, 2000) , and this is generally considered to be due to the efficiency by which HDL returns cholesterol to the liver for metabolism and excretion, resulting in reduced serum cholesterol availability (Barter & Rye, 1994) .
The elevated levels of the lipoprotein (LDL) and (VLDL) are usually associated with atheroma formation. Therefore, defects in cholesterol metabolism are a major cause of cardiovascular disease, this is apparent in patients with familial hypercholesterolemia, characterized by grossly elevated levels of serum cholesterol, in particular LDL. Reduction of plasma LDL-85 cholesterol (in patients with elevated levels) is associated with a decreased incidence of coronary heart disease (CHD) (Anderson; Boden; Farnier; Fruchart and Gordon). Also, there is an increasing evidence that serum triglycerides (TGs) are strong risk factors in cardiovascular disease in many patients with normal circulating LDL-cholesterol, but with high levels of plasma TGs and concomitantly low levels of HDL-cholesterol (Cullen; Krauss and Rubins).
LDL-cholesterol has been well established as an independent risk factor since reporting of the 1948 Framingham study (Gordon et al. 1977) . HDL-cholesterol is recognized as being a negative risk factor for CHD . While LDL cholesterol is a major health factor, here are a few other factors that can contribute to the progression of athero. The need for more rapid drug development highlights the role that surrogate markers may play in establishing the efficacy of drugs for managing CVD, and more specifically, atherosclerosis (Revkin et al. 2007 ).
a. Lipid markers of atherosclerosis:
Plasma levels of lipids and lipoproteins have been well established as strong predictors of CHD. There is, also, a stronger positive correlation of apolipoproteins (apo) with atherosclerosis and coronary events than that of the plasma lipoproteins, either cholesterol carried by lipoprotein particles or their actual concentration expressed as apo B and apo A-I.
Lipoproteins are spherical molecules that transport different amounts of cholesterol and triglycerides in the blood stream. LDL and HDL particles are rich in cholesterol, while VLDL and chylomicron particles predominantly transport triglycerides The apo B is present on the surface of LDL, VLDL and chylomicrons (one molecule at each particle), while apo A-I resides on HDL particles (Fig.4) . Lipoprotein (a) consist of two main components: lowdensity lipoprotein (LDL) and apolipoprotein (apo) (a) linked by a single disulphide bond between the C terminal of apo B100 and apo(a) kringle (K) IV type 9.The LDL particles may differ among individuals in the cholesteryl ester content of the lipid core that is surrounded by a monolayer of phospholipids, unesterified cholesterol, and apo B100. Apo (a) is made of 10 different type IV kringles (1-10) followed by kringleV and a catalytically inactive protease domain (P), (Angelo M. et al. 2008 ).
Conventional lipid tests determine the amount of cholesterol and triglycerides transported by all particles within the lipoprotein classes or in total plasma. Thus, cholesterol and triglycerides may be regarded as surrogate markers for their carrier-lipoprotein particles. 
Non-HDL cholesterol:
Another approach to the measurement of atherogenic lipoproteins is the use Non-HDL cholesterol which is easily calculated by deducting the HDL cholesterol from the total cholesterol value, with no need for previous fasting of the patient. This is the cholesterol contained in VLDL and LDL particles, atherogenic triglyceride-rich lipoproteins, cholesteryl ester-enriched remnants of triglyceride-rich lipoproteins, and lipoprotein(a). Consequently, the non-HDL cholesterol is essentially the cholesterol analogue to an apo B level. The non-HDL cholesterol content is easily available within the primary screening of the lipid profile, and according to the recommendations of NCEP ATP III it is identified as a secondary therapeutic target after achieving the target levels of LDL cholesterol. (JMB, 2008, 27:148 -153).
b. Circulating markers of inflammation and atherosclerosis:
Epidemiologic and prospective studies evaluating the predictive value of the variety of circulating markers of vascular inflammation such as C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA), leukocyte count in peripheral blood, immunoglobulin, adhesion molecules, cytokines and chemokines has been well established. Population studies demonstrated a moderate elevation of serum fibrinogen and leukocyte count in peripheral blood in individuals subsequently developed atherosclerotic disease. Increased fibrinogen levels were identified as strong predictors of stroke (JMB, 2008, 27:148 -153).
Metabolic syndrome
The metabolic syndrome has emerged in recent years as a major public health concern. By 2002 it was estimated that as many as 24% of American adults suffer from the metabolic syndrome as defined by the ATPIII criteria*).Individuals suffer from the metabolic syndrome have been demonstrated to be at increased risk of the development of hypertension, atherosclerosis, type II diabetes and cardiovascular disease. The term 'metabolic syndrome' refers to a cluster of metabolic abnormalities associated primarily with obesity including elevated plasma triglycerides (TG), low-density lipoprotein (LDLcholesterol), and very low-density lipoprotein (VLDL-cholesterol), reduced high-density lipoprotein (HDL-cholesterol), and elevations in blood pressure and fasting glucose.
Dyslipidemia
Dyslipidemia is a disruption in the amount of lipids in the blood either by increase or decrease. Most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood, often due to diet and lifestyle. The increased type of dyslipidemia could be differentiated as: 
Managing cholesterol
The elevated levels of the lipoprotein (high cholesterol level) may depend on the lifestyle of the patient. Eating a lot of fats and not getting enough exercise can cause cholesterol levels to rise. It's also, in part, a result of the genetic makeup. Some people inherit genes associated with elevated levels of cholesterol. One type is called familial hypercholesterolemia. People with this genetic makeup can eat a healthy diet and exercise, and still have high cholesterol. Managing high cholesterol may be different for one patient to another depending on the medical history and the health of the patient. Therefore, cholesterol test, also known as a fasting lipid profile, and, along with complete medical background can work together to manage cholesterol. 
Cholesterol guidelines
The antiatherosclerotic activity
The antiatherosclerotic activity is exerted via both cholesterol lowering and direct ACAT inhibition in plaque macrophages. Cholesterol esters (CE) are the main lipid components responsible for the development of atherosclerosis; hence they are present in the foam cells and extracellular plaque matrix, and susceptible to oxidation that could increase their atherogenic potential.
The treatment using novel ACAT inhibitor pactimibe sulfate (CS-505), avasimibe (CI-1011) (Fig.6) , and a potent bile acid binding resin cholestyramine directly affects macrophages in atherosclerotic lesions. They would limit the increase in intracellular free cholesterol by its TC-lowering effect. This would allow free cholesterol to excrete into HDL, restoring the cholesterol influx/efflux balance, thus preventing foam cell formation. (Terasak N. et al.
2007).
Lipid lowering drugs (LLD)
Lipid-lowering drugs (LLD) or agents are a diverse group of pharmaceuticals that are used in the treatment of hyperlipidemia; some may lower "bad cholesterol" (LDL) more so than others, while others may prudentially increase (HDL), "the good cholesterol". Other studies showed that elevating the high-density lipoprotein (HDL), as well as, lowering the lowdensity lipoprotein (LDL) and triglyceride levels (TGs) in the serum are accepted measures in treating hyperlipidemia and atherosclerosis.
Clinical trials
The lipid lowering in hyperlipidemia is achieved clinically using statins and fibrate drugs. Since 1966, there have been 16 major trials investigating the efficacy of statin and fibrate therapy, both as a single drug treatment and as part of a multi-drug regimen (Napoli C. et al. 1997 ). These trials have involved the participation of some 30,000 patients, and have considered both primary and secondary prevention of coronary heart disease (CHD), myocardial infarction, stroke, and peripheral artery disease (Tylor, Faergeman, Boden) . Studies by Nagao et al. (1998) , involved the use of fibrate gemfibrozil to reduce cholesterol levels in hypercholesterolemia rats fed a cholesterol rich diet.
Other studies have confirmed these results (Bruckert and Rustemeijer), while some trials involving gemfibrozil, bezafibrate, and fenofibrate indicated that fibrates can reduce LDLcholesterol to a degree comparable with that observed with statins (Feussner; Guay and Haffner). Most of the studies are of the general conclusion that statins are the drug of choice where the major dyslipidaemia is high-baseline LDL-cholesterol and that fibrates are particularly effective in the case of hypertriglyceridaemia (Farnier M. 1998 ). Other studies have confirmed these results while some trials involving bezafibrate, gemfibrozil, and fenofibrate indicated that fibrates can reduce LDL-cholesterol to a degree comparable with that observed with statins (Guay DR. 1999).
2. The well-established lipid lowering drugs 1. Statins: Current ATPIII guidelines for the treatment of patients with the metabolic syndrome encourage therapies that lower LDL-cholesterol and TG, and raise HDLcholesterol. Primary intervention often involves treatment with statins to improve the lipid profiles of these patients. Statins act by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A, (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway in the liver (Fig.7) , thus stimulates the LDL-receptors resulting in an increased clearance of LDL from the blood stream and a decrease in blood cholesterol levels. The first result can be seen after one week of use and the effect is maximal after four to six weeks. Statins are particularly well suited for lowering LDL in people at risk for cardiovascular diseases because of hypercholesterolemia . 2. Fibrates: Although fibrates ( e,g. clofibrate 2) are used clinically since the early 1970s, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα. The PPARs are a class of intracellular receptors that modulate carbohydrate, fat metabolism and adipose tissue differentiation (Staels B. 1998) ; (Fruchart JC. et al. 1999 ). They typically lower triglyceride by 20% to 25%. The newer generation fibrates: gemfibrozil (3) Bezafibrate (4) (Spieker LE. et al. 2000) , and Fenofibrate (5) afford significant protection from CHD; this might be due to the agonistic effect of PPARα that inhibits inflammatory responses at the level of the vascular wall. Finally, evidence that fibrates are able to reduce levels of plasma fibrinogen, which, in turn, reduces the likelihood of thrombogenesis (Helen et.al. 2002) .
Clofibrate (2) Ethyl 2-(4-chlorophenoxy)-2-methylpropanoic acid
Gemfibrozil ( 3. Niacin: 3-pyridinecarboxylic acid . also know as nicotinic acid or vitamin B3, the name niacin was derived from nicotinic acid + vitamin, it is also referred to as "vitamin PP", a name derived from the absolute term "pellagra-preventing factor". Over the years, niacin has gained recognition as an atheroprotective agent, in part because of its capacity to lower the plasma levels of cholesterol, triglycerides by 20-50%., and verylow-and low-density lipoproteins. It may lower LDL by 5-25% and to substantially raise high-density lipoprotein. by 15-33%..In high doses, niacin has also been reported to lower the plasma level of lipoprotein (a) nonabsorbed, polymeric, lipid-lowering agent that binds with bile acids in the intestine and significantly reduces their reabsorption. As the bile acid pool becomes depleted, there is an increased conversion of cholesterol to bile acids, thereby reducing cholesterol concentrations. The mechanism of action of colesevelam is similar to that of cholestyramine (e.g., Questran) and colestipol (Colestid). However, the new drug has a greater binding affinity for bile acids, permitting the use of a lower dosage, and appears to have a lower incidence of gastrointestinal (GI) adverse events and a lower potential for drug interactions. Colesevelam is indicated for use, alone or in combination with a hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (a "statin"), as adjunctive therapy to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia (Fredrickson Type IIa). In the clinical studies, colesevelam reduced LDL-C concentrations by 15% to 18%, and increased high-density lipoprotein cholesterol (HDL-C) concentrations by 3%. There were small increases in triglyceride concentrations, but these were not statistically different from the results in those receiving placebo. 6. Phytosterols: have cholesterol-lowering properties; reducing cholesterol absorption in intestines, and may act in cancer prevention. Phytosterols naturally occur in small amount in vegetable oils, especially soybean oil. Sterols can reduce cholesterol in human subjects by up to 15% (Rossi S, 2006).
Ergosterol (9)
β-Sitosterol (10) 
Synthetic hypolipidemic agents
A continued research effort has been underway over the past several years in the area of the development of hypolipidemic agents (Chapman JM. et al. 1979&,1983 .
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Chapman and co-workers initially reported the hypolipidemic activity of phthalimides and N-substituted phthalimides including alkyl, methyl ketone, carboxylic acids, and acetate esters of varying chain length were synthesized and tested for hypolipidemic activity in mice, compounds (1), (2), and (3) were found to afford the most significant reduction in serum cholesterol and triglyceride levels. Phthalimides, the parent compound, decreased serum cholesterol and triglyceride levels by 43% and 56% respectively, in mice after 16 days of dosing at an optimum dose of 20mg/kg/day (Chapman JM. et al. 1979 )
The hypolipidemic effects of aromatic versus non aromatic imides were investigated. Thus, a number of N-substituted phthalimides (4),1,8-naphthalimide (5), succinimide (6), and glutarimide (7) derivatives demonstrated significant hypolipidemic activity at 20 mg/kg/day in male mice (25gm) after16 days of intrapretonially dosing. The dose of 20 mg/kg/day was selected for structure activity relationship SAR study because this dose proved to be the optimum dose when testing phthalimides and 3-N-(1,8-naphthalimide)propionic acid. Most of the derivatives at 20mg/kg/day demonstrated improved activity over clofibrate at 150mg/kg/day. In general, 1,8-naphthalimide and glutarimide derivatives appeared to be less active than phthalimides and succinimide. Removal of phenyl ring of phthalimides resulting in succinimide led to less hypolipidemic activity in general. The loss of aromatic system of 1,8-naphthalimide resulting in glutarimide led to a slight loss of anticholesterolemic activity and only α-phenylglutarimide show slight improvement of antitriglyceridemic activity ).
The importance of rigid imide ring system for hypolipidemic activity was determined. Therefore, two series of cyclic imides; diphenimide (8) and its open acyclic imides; dibenzimide (9), and succimide (10), and diacetimide (11) were examined for hypolipidemic activity in mice. It was shown that the rigid imide ring system was not necessary for hypercholesterolemia activity. However, the cyclic imide's structure was a necessary requirement for a good hypotriglyceridemic activity (Voorstad. et.al. 1985) .
A series of nitrogen substituted N-butan-3-one derivatives of cyclic imides; such as phthalimides (12), o-benzosulphimide (13), 1,8-naphthalimide (14), and diphinimide (15) were prepared (Chapman JM. et al. 1990) . 
Molecular modeling programs were used to compare the 3D structures of the some derivatives of some cyclic imides with the already known Clofibrate (2) (ethyl ester of 2,2-dimethylphenoxyacetic acid), These overlays were made with the aid of computer Accelry's soft wares at the Computer laboratory, Faculty of Pharmacy, KAU, KSA.
The Changes in the structure of phthalimide involving the imide's ring system led to the preparation of new compounds with potent and significant antihyperlipidemic effect; this is due to the good efficacy of their binding to the fatty acid receptor sites (Hall IH et al. 1986 ).
The promising hypolipidemic activity of certain cyclic imides derivatives in experimental animals strongly potentiate and recommend more researches in this area 
